Bevacizumab combined with chemotherapy vs single-agent therapy in recurrent glioblastoma: evidence from randomized controlled trials

Overview of attention for article published in Cancer Management and Research, July 2018

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 17 Dimensions

Readers on

mendeley: 16 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 17 publications that cite this research output.

17

The most recent citing publications are shown below. View all 17 publications that cite this research output on Dimensions.

Tetrazolium–based colorimetric assays underestimat the direct antitumor effects of anti-VEGF agent bevacizumab

Article in Toxicology in Vitro (June 2023)

Efficacy and Safety of Bevacizumab for Treating Glioblastoma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials

Article in Cancer Investigation (February 2023)

Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study

Article in Clinical Medicine Insights Oncology (January 2023)